金属钌复合物在泌尿系肿瘤中的研究进展

发布时间：2018-05-01 03:21

  本文选题：钌复合物 + 泌尿系肿瘤　； 参考：《实用医学杂志》2017年22期

【摘要】：金属铂类药物作为抗肿瘤药物已经广泛应用于临床,然而铂类药物存在许多缺点,比如明显的毒副作用、药物耐受性以及低水溶性,产生了寻找替代含过渡金属的抗肿瘤药物的需要。为了克服这些缺点,金属钌复合物应运而生并且展现出良好的前景。金属钌复合物在体内和体外都显示了良好的药物学性能,同时具有低毒和良好选择性,并且能克服顺铂耐受的缺点。因此,针对金属钌复合物的良好抗肿瘤性能,有望改善泌尿系肿瘤的治疗现状。本文主要对近年来金属钌复合物在泌尿系肿瘤中的研究进展进行综述。
[Abstract]:Metal platinum drugs have been widely used in clinic as antitumor drugs. However, platinum drugs have many disadvantages, such as obvious side effects, drug tolerance and low water solubility. There is a need to find alternative anti-tumor drugs containing transition metals. In order to overcome these shortcomings, ruthenium complexes emerge as the times require and show good prospects. Ruthenium complexes exhibit good pharmacological properties in vivo and in vitro, low toxicity and selectivity, and can overcome the shortcomings of cisplatin tolerance. Therefore, the excellent anti-tumor performance of ruthenium complexes is expected to improve the current status of urological tumor treatment. In this review, the recent advances in the research of ruthenium complexes in urological tumors were reviewed.
【作者单位】： 广东医科大学附属医院泌尿外科;
【基金】：国家自然科学基金资助项目(编号:8140102155)
【分类号】：R737.1
，

本文编号：1827510